MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first line of mushroom-based nootropics now available for sale.
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
U.S. Psychedelic Drug Legalization: Urgency or Inertia?
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Transatlantic Capital, Inc. Announces Plan To Initiate Early Phases of Cannabis and Psilocybin Production in the Aftermath of Their Most Recent Land Acquisition
PORTLAND, OR / ACCESSWIRE / February 16, 2021 / Transatlantic Capital Inc. (OTC PINK:TACI) announces their plan to begin early stages of mass Cannabis and Psilocybin Mushroom production by early 2021. As mentioned in a previous announcement from October 22nd, 2020, Transatlantic Inc., or "TACI" finalized a land deal that gave them over 250 acres of rural property in Clarendon, Jamaica which will allow them to safely produce and manufacture their medicinal products.
Why psychedelics are a more ‘compassionate’ way to treat trauma
THE PAST DECADE has been witness to a renaissance in psychedelics research.